Etimumotide

艾替莫肽

Report date: 2026/04/28 20:00:22

Base Information

Drug NameEtimumotide
Drug Alias NameIO-103
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSmoldering Multiple MyelomaCarcinoma, Basal CellLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHerlev HospitalIo Biotech Aps
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of CopenhagenIo Biotech Aps
Active IndicationsN/A
Inactive IndicationsSmoldering Multiple MyelomaCarcinoma, Basal CellLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A